Tag: European anticoagulant market expansion
Akums Secures First UK MHRA Approval for Rivaroxaban
With Akums as the Marketing Authorisation holder, the approval validates the company’s robust quality systems and regulatory expertise. Rivaroxaban, an oral anticoagulant, is prescribed for NVAF, DVT, PE, and cardiovascular risk reduction.